Alteogen Eyes First-Mover Advantage For Eylea Biosimilar
Cites Benefit Of Formulation Patent As Aflibercept Rival Completes Phase I Trial
Korea’s Alteogen believes that formulation patents granted in the EU, US and Japan as well as a pending process patent may offer it a first-mover advantage on biosimilar aflibercept. The firm has just completed a Phase I trial for its proposed rival to Eylea.
